Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Carbopol 974P is a polymer used as a lacrimal substitute to treat symptoms associated with dry eyes. Carbopol 974P is a highly carboxylated polymer composed of lightly cross-linked polyacrylic acid with a broad-spectrum mechanism based on acidification of pathogens.
- Mechanism
- Curator reviewed
BufferGel is a microbicidal spermicide that provides sufficient buffering activity to maintain the mild, protective acidity of the vagina in the presence of semen. Sperm are acid-sensitive, so to assure fertility, semen provides a powerful alkalinizing action that abolishes the protective acidity of the vagina for several hours after intercourse. This alkalinizing action of semen also enables acid-sensitive sexually transmitted diseases (STD) pathogens to transmit infection. By blocking this action of semen, BufferGel prevents unwanted pregnancy, and shows promise for prevention of STDs, including HIV/AIDS.
- Primary indication
- Investigated for use/treatment in contraception and HIV prevention.Curator reviewed · 3 structured indications
- Also known as
- Carbomer 974 (P) · Carbomer 974P · Carbomer homopolymer type B · Carbomer-974P · Carbopol polymer
Resolves to
What you can answer from here — as of April 02, 2025
Which other approved drugs treat the same conditions as Carbopol 974P, and which companies have late-stage candidates in those indications?